Cencora, Inc. (NYSE:COR) has priced $3 billion in senior notes with maturities ranging from 2029 to 2056. The pharmaceutical solutions company plans to use the proceeds primarily to repay existing debt related to its OneOncology acquisition, with any remainder going towards general corporate purposes. Cencora is a Fortune 500 company with a market cap of approximately $70 billion and has shown significant stock performance over the past year.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Cencora prices $3 billion in senior notes across multiple maturities By Investing.com
Cencora, Inc. (NYSE:COR) has priced $3 billion in senior notes with maturities ranging from 2029 to 2056. The pharmaceutical solutions company plans to use the proceeds primarily to repay existing debt related to its OneOncology acquisition, with any remainder going towards general corporate purposes. Cencora is a Fortune 500 company with a market cap of approximately $70 billion and has shown significant stock performance over the past year.